Ann: iPPS shows 3-year equivalent durability in OA Canine Study, page-43

I’ve just reviewed the last 12 months ASX announcements at PAR.

No wonder Paul Rennie and Helen Fisher bought on market recently. We have put pain and function beyond doubt with our 2 Phase2b trials, with substantial therapeutic duration effects and disease modification signals at 6 months read out. Our blood work up, serum and scans (X-ray MRI) indicating disease modification and genuine Pain and Function improvements for months post final injection in our cohort of grade 3-4 OA subjects. Impressive.

Human/Canine data pointing in the same direction as human data, which now gives us confidence we get the 12 month data at 008 which enhances our dataset for DMOAD with USA FDA.

MPS joint venture looming now, OA deals must be less than 12 months away now. The size of the cap raise in 2022 may only make perfect sense after we do our deals. Or obtain our accelerated approval from USA FDA.

Enquiries would be building.

Exciting times at PAR.